SELLAS Life Sciences (SLS) Non Operating Income (2012 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Non Operating Income of $845000.0 for Q1 2026, up 238.0% year-over-year from $250000.0 in Q1 2025, and up 41.54% quarter-over-quarter from $597000.0 in Q4 2025.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Non Operating Income (2012 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Non Operating Income for 11 consecutive years, with $845000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 238.0% year-over-year to $845000.0; the TTM figure through Mar 2026 stood at $2.0 million (up 149.81% YoY), while the FY2025 annual figure was $1.4 million, up 123.26% from the prior year.
- Non Operating Income improved to $845000.0 in Q1 2026 per SLS's latest filing, from $597000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $845000.0 in Q1 2026 and bottomed at $37000.0 in Q4 2023.
- Historically, Non Operating Income has averaged $254437.5 across 5 years, with a median of $209500.0 in 2022.
- Annual changes were most pronounced in 2023 — Non Operating Income plunged 88.62% — and 2024, when it soared 389.19%.
- SELLAS Life Sciences' Non Operating Income stood at $325000.0 in 2022, then slumped by 88.62% to $37000.0 in 2023, then jumped by 389.19% to $181000.0 in 2024, then jumped by 229.83% to $597000.0 in 2025, then jumped by 41.54% to $845000.0 in 2026.
- Business Quant data shows SLS's Non Operating Income at $845000.0 in Q1 2026, $597000.0 in Q4 2025, and $292000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | 1.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Mn |
| Mar 31, 2026 | 845,000.00 |
| Dec 31, 2025 | 597,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 272,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 221,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | 184,000.00 |
| Dec 31, 2022 | 325,000.00 |
| Sep 30, 2022 | 124,000.00 |
| Jun 30, 2022 | 209,000.00 |
| Dec 31, 2019 | -7.50 Mn |
| Sep 30, 2019 | -4.20 Mn |
| Jun 30, 2019 | -3.13 Mn |